Drug Profile
Polyclonal antibody TriTAb
Alternative Names: Polyclonal antibody TriTAb - Protherics; TriTAbLatest Information Update: 09 Oct 2001
Price :
$50
*
At a glance
- Originator Protherics
- Class Antidotes; Polyclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Poisoning
Most Recent Events
- 09 Oct 2001 Discontinued-II for Poisoning in USA (Unknown route)
- 19 Dec 2000 Protherics have reaquired the distribution rights of TriTab from Altana in the USA
- 18 Oct 1999 Therapeutic Antibodies has merged with Proteus International to form Protherics